zoledronic acid has been researched along with Fatty Liver, Nonalcoholic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, W; Jiang, S; Li, C; Qiu, Y; Shen, D; Tang, Q; Xue, B; Zhao, Y | 1 |
| Ezzat, SF; Hamam, GG; Mohamed, RH; Tarek, M | 1 |
| Anastasilakis, AD; Arsos, G; Kita, M; Kountouras, J; Litsas, I; Moralidis, E; Polyzos, SA; Terpos, E | 1 |
3 other study(ies) available for zoledronic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis.
Topics: Animals; Diphosphonates; Enzyme Activation; Geranyltranstransferase; Humans; Imidazoles; Lipogenesis; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; rhoA GTP-Binding Protein; Zoledronic Acid | 2017 |
Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cytoprotection; Diet, High-Fat; Fasting; Liver; Male; Mevalonic Acid; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2019 |
Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.
Topics: Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Diphosphonates; Fatty Liver; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Non-alcoholic Fatty Liver Disease; Osteitis Deformans; Radionuclide Imaging; Zoledronic Acid | 2011 |